Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 28, 2011

Premium

Title: Multiple RNA Polymerase III Promoter-Expression Constructs

Patent Number: 7,985,581

Filed: Aug. 23, 2005

Lead Inventor: Catherine Pachuk, Nucleonics (Alnylam Pharmaceuticals)

The patent, its abstract states, claims “expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule. ... Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which may comprise single and/or multiple fingers. The provided constructs are useful for in vivo delivery of RNA molecules effective in gene silencing, including of viral genes including HBV and HCV.”


Title: microRNA Fingerprints During Human Megakaryocytopoiesis

Patent Number: 7,985,584

Filed: March 19, 2007

Lead Inventor: Carlo Croce, Ohio State University

The invention comprises “novel methods and compositions for the diagnosis, prognosis, and treatment of cancer and myeloproliferative disorders,” the patent's abstract states. “The invention also provides methods of identifying anti-cancer agents.”


Title: RNA Interference-Mediated Inhibition of Platelet-Derived Growth Factor and Platelet-Derived Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,985,853

Filed: May 11, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor and/or platelet derived growth factor receptor gene expression using short interfering nucleic acid (siNA) molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of platelet derived growth factor and/or platelet derived growth factor receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.”


Title: siRNA Targeting TATA Box Binding Protein-Associated Factor

Patent Number: 7,985,854

Filed: Aug. 10, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fischer Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1.”


Titles: Targeting PAX2 for the Induction of DEFB1-Mediated Tumor Immunity and Cancer Therapy

Application Numbers: 20110177075, 20110177100, 20110177101, 20110178162

Filed: Jan. 19, 2011

Inventor: Carlton Donald, Medical University of South Carolina

The invention, the patent application's abstract states, comprises “a method of treating cancer in a subject by inhibiting expression of PAX2. … In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.”


Title: Delivery of Nucleic Acids Across Membranes

Application Number: 20110177599

Filed: July 20, 2010

Inventor: Camille Diges, Bio-Rad

The invention provides “methods and compositions for introducing integral membrane proteins into cell membranes and, optionally, delivery of nucleic acids across membranes via the integral membrane proteins,” the patent application's abstract states.


Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer Using miR-17-3P

Application Number: 20110177968

Filed: March 30, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.”


Title: Silencing of CSN5 Gene Expression Using Interfering RNA

Application Number: 20110178155

Filed: Oct. 13, 2010

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent application's abstract states, “provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the … invention provides unmodified and chemically modified interfering RNA molecules [that] silence CSN5 gene expression and methods of use thereof. … [The] invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.”


Title: Modulation of HSP47 Expression

Application Number: 20110178157

Filed: Dec. 8, 2010

Lead Inventor: Xiaomei Jin, Nitto Denko (Quark Pharmaceuticals)

The invention, the patent application's abstract states, comprises “compositions, methods, and kits for modulating expression of target genes, particularly heat shock protein 47. The compositions, methods, and kits may include nucleic acid molecules that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, and kidney fibrosis.“


Title: Ribonucleic Acid Interference Molecules and Binding Sites Derived by Analyzing Intergenic and Intronic Regions of Genomes

Application Number: 20110178283

Filed: April 21, 2006

Lead Inventor: Isidore Rigoutsos, IBM

The patent application, its abstract states, comprises “sequences that can be used in the context of controlled gene regulation.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.